The marketing authorization in China for ivonescimab, based on positive Phase III trial results, is a significant milestone for Summit Therapeutics. This approval is likely to boost investor confidence and drive the stock price higher. Additionally, the $200 million raised through a stock offer provides the company with substantial capital to further develop ivonescimab and support other corporate purposes.